---
title: "Eli Lilly Reports Phase 1 Ovarian Cancer Combination Results"
canonical: "https://thestockmemo.com/article/eli-lilly-reports-phase-1-ovarian-cancer-combination-results"
markdown: "https://thestockmemo.com/article/eli-lilly-reports-phase-1-ovarian-cancer-combination-results.md"
type: article
published: "2026-10-27T11:23:29.587169+00:00"
updated: "2026-10-27T11:23:29.587169+00:00"
company: "Eli Lilly & Co"
ticker: "LLY"
isin: "US5324571083"
price_as_of: "2026-10-27T08:00:33.552+00:00"
image: "https://thestockmemo.com/media/770f4fca-0d5a-4d11-8782-7ee902066c6a.png"
tags:
  - "Global"
  - "Pharmaceuticals"
  - "Stock Analysis"
---

# Eli Lilly Reports Phase 1 Ovarian Cancer Combination Results

> The combination of sofetabart mipitecan and bevacizumab produced a 79% confirmed objective response rate and a 100% disease control rate in a Phase 1 cohort of platinum-sensitive ovarian cancer patients.

Eli Lilly reported Phase 1 results for sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer, with a 33-woman cohort showing a 79% confirmed objective response rate and a 100% disease control rate among 29 evaluable patients.

## Key figures

| Field | Value |
| --- | --- |
| Company | Eli Lilly & Co |
| Ticker | LLY · NYSE |
| ISIN | US5324571083 |
| Sector | Pharmaceuticals |
| Price | $1,279.14 |
| Price target | $1,317.93 |
| Upside | +3.0% |
| Fair Value | $980.00 |
| Rating | Buy |
| Sentiment | Positive |

## What happened

Eli Lilly & Co (NYSE: LLY) reported Phase 1 results for sofetabart mipitecan (Sofe-M) plus bevacizumab in platinum-sensitive ovarian cancer.

The combination produced a 79% confirmed objective response rate and a 100% disease control rate.

The Phase 1 cohort included 33 women. The response rates come from evaluable patients with measurable disease. We read these as early observations, not established clinical benefit.

## Why it matters

A confirmed objective response rate of 79% or higher held in both PARP inhibitor-treated and PARP inhibitor-naive patients. Median duration of response and median progression-free survival had not been reached at median follow-ups of 6.2 and 10.2 months, respectively.

The FRAmework-01 program is evaluating Sofe-M in three global Phase 3 trials across platinum-resistant and platinum-sensitive ovarian cancer. We think those ongoing trials, rather than this cohort, could be the test of whether the combination delivers clinical benefit.

## By the numbers

The confirmed objective response rate reached 79.3% among the 29 evaluable patients with measurable disease at the July 6, 2026, data cutoff.

- Six of those patients had a complete response, 20.7% of the group.
- Another 17 had a partial response, 58.6% of the group.
- Patients had received a median of three prior systemic regimens.
- 67% had received a prior PARP inhibitor.
- 70% had received prior bevacizumab.

Epistaxis (nosebleeds) and nausea were the most common adverse events of any grade, each occurring in 73% of patients.

- Neutropenia was the most common Grade 3 or higher treatment-emergent adverse event, affecting 42% of patients.
- Grade 3 or higher anemia occurred in 24% of patients.
- Dose reductions occurred in 42% of patients.
- 6% of patients discontinued treatment due to an adverse event.
- Any-grade neuropathy occurred in 9% of patients, with no Grade 3 or higher events.

---

## Legal notices

The content on The Stock Memo is general information only. It is not investment advice, a research report prepared for you, or an offer or solicitation to buy or sell any security. Frontier Media Inc. is not a registered investment adviser or broker-dealer.

Investing in securities can result in a total loss of the money you put in. Past prices and past results are not a reliable guide to the future. Statements about what may happen later can turn out differently. Prices shown here may be delayed and are not a basis for a trade.

Frontier Media Inc., its staff, or people connected with them may hold positions in securities discussed on the site. Where we know of a conflict, we say so next to the relevant content.

**Artificial intelligence.** Our studies and articles are produced with the help of AI systems, and the images in page headers are AI-generated symbols. Which systems we use, and who is responsible for the content, is described under [AI Disclosure](/legal/ai-disclosure).

Decide for yourself. If you need advice that takes your own finances into account, ask someone who is qualified and registered to give it.

Source: https://thestockmemo.com/article/eli-lilly-reports-phase-1-ovarian-cancer-combination-results